Compare Amgen, Inc. (AMGN) vs Lemonade Inc (LMND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Lemonade Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Lemonade Inc trades at $70.65 (market cap $5.42B). The key difference: Amgen, Inc. is far larger — about 36.2× Lemonade Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| AMGN | LMND | |
|---|---|---|
Market Cap | $196.12B | $5.42B |
Sector | Health | Financials |
52-Week High | $388.16 | $96.57 |
52-Week Low | $271.18 | $36.28 |
Enterprise Value | $241.41B | $5.24B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Lemonade (LMND) trades at $70.51, up 0.26% today, with a bullish technical signal from moving averages and strong support at $69. The company shows accelerating revenue growth, with 2025 revenue reaching $738 million, while narrowing net losses to -$166 million. Recent news highlights expansion into new states and reinsurance program improvements, though the stock faces a mixed analyst consensus with 33% buy ratings.
Outlook remains speculative given persistent losses but improving margins; key opportunities include AI-driven growth and market expansion, while risks involve high valuation multiples and profitability timeline uncertainty. The consensus price target of $67 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
